MedTrace Logo

MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

NCT03406962 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-11-03

Study results available
· View outcomes & findings →

Summary

This study is designed to assess the safety and efficacy of using MGTA-456 in patients with Inherited Metabolic Disorders (IMD) undergoing stem cell transplantation.

Conditions

  • Inherited Metabolic Disorders (IMD)

Interventions

DRUG

MGTA-456

Hematopoietic stem cell transplantation will be done with the cell therapy product MGTA-456.

Sponsors & Collaborators

  • Magenta Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Magenta Study Coordinator · Magenta Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
0 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-09
Primary Completion
2020-02-10
Completion
2021-01-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03406962 on ClinicalTrials.gov